Review
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 16, 2022; 10(11): 3321-3333
Published online Apr 16, 2022. doi: 10.12998/wjcc.v10.i11.3321
Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma
Min Yao, Jun-Ling Yang, De-Feng Wang, Li Wang, Ying Chen, Deng-Fu Yao
Min Yao, Research Center of Clinical Medicine & Department of Immunology, Medical School of Nantong University, Nantong 226001, Jiangsu Province, China
Jun-Ling Yang, De-Feng Wang, Deng-Fu Yao, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China
Li Wang, Department of Medical Informatics, Medical School of Nantong University, Nantong 226001, Jiangsu Province, China
Ying Chen, Department of Oncology, Affiliated Second Hospital of Nantong University, Nantong 226001, Jiangsu Province, China
Author contributions: Yao M, Yang JL, and Wang DF contributed equally to this work and wrote the first draft of the paper; Wang L and Chen Y performed the literature search for the manuscript; Yao M and Yao DF revised the manuscript and edited all drafts of the paper; all authors approved the final version of the manuscript.
Supported by the National Natural Science Foundation of China, No. 84673241, No. 81873915 and No. 31872738; and Nantong S&T Development Plan, No. MS12020021, and No. MS12019016.
Conflict-of-interest statement: The authors report no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Deng-Fu Yao, MD, PhD, Director, Full Professor, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, No. 20 West Temple Road, Nantong 226001, Jiangsu Province, China. yaodf@ahnmc.com
Received: March 19, 2021
Peer-review started: March 19, 2021
First decision: May 1, 2021
Revised: May 10, 2021
Accepted: May 25, 2021
Article in press: May 25, 2021
Published online: April 16, 2022
Processing time: 385 Days and 10.1 Hours
Core Tip

Core Tip: Tissues in hepatocellular carcinoma (HCC) or hepatocyte malignant transformation can express and secrete a variety of molecules such as specific biomarkers or oncogenic antigens into blood. These biomarkers not only contribute to the diagnosis or prognosis of HCC, but may also become molecular targets for HCC therapy under developing or clinical trials. This article reviews the recent novel progress of some emerging biomarkers in basic studies or clinical trials for HCC immunotherapy.